Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy

Biomarkers that facilitate the prediction of disease recurrence in prostate cancer (PCa) may enable physicians to personalize treatment for individual patients. In the current study, PD-1 (PDCD1) promoter methylation was assessed in a cohort of 498 PCa patients included in The Cancer Genome Atlas (T...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Goltz, Diane, Gevensleben, Heidrun, Dietrich, Jörn, Ellinger, Jörg, Landsberg, Jennifer, Kristiansen, Glen, Dietrich, Dimo
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087295/
https://ncbi.nlm.nih.gov/pubmed/27853645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1221555
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky